Tafasitamab sold to IncyteNovartis to launch a voluntary public takeover offer for all MorphoSys shares at a price of € 68.00 per share in cashShareholders benefit from attractive premium of 94 percent to the one-month volume weighted average price before January 25, 2024Novartis provides ample resources to maximize...

Related Keywords

Germany , United States , Munich , Bayern , Planegg , Canada , Boston , Massachusetts , America , German , Jean Paul Kress , Meagher Flom , Incyte , Eamonn Nolan , Julia Neugebauer , Thomas Biegi , Drug Administration , Incyte Corporation , Company Annual Report On Form , Twitter , Exchange Commission , Constellation Pharmaceuticals Inc , German Federal Financial Supervisory Authority Bafin , German Federal Financial Supervisory Authority The Bafin , Corporate Affairs , Xencor Inc , Lymphoma Society , Corporate Communications Investor Relations , Novartis , Linkedin , Supervisory Board , Business Combination Agreement , Purchase Agreement , Chief Executive Officer , Novarti Public Takeover , Certain Cash Value , Morphosy Shareholders , New Opportunities , Morphosy Colleagues , Morphosy Management Board , German Securities Acquisition , Takeover Act , German Federal Financial Supervisory Authority , Tender Offer Statement , Recommendation Statement , Morphosy Purchase Agreement , Analyst Call , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis , Prescribing Information , Takeover Offer , Takeover Offer Documents , Recommendation Statements , Annual Report , Vice President , Global Head , Corporate Communications ,